Basiliximab Product Approval Information - Licensing Action

Proper name: Basiliximab
Tradename: Simulect
Manufacturer: Novartis Pharmaceutical Corp, East Hanover, NJ, License #1244
Indication for Use: Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids
Approval Date: 5/12/98
Type of submission: Biologics license application


Approval Letter (PDF)

SBA memo (PDF)

Label (PDF)

Reviews (PDF)
    Chemistry, Manufacturing and Controls (20 pages)
    Clinical Efficacy and Safety (36 pages)
    Clinical Pharmacology (17 pages)
    Product (30 pages)
    Pharmacology (3 pages)
    Statistical (17 pages)

Page Last Updated: 05/13/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English